Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.RegeneRx Biopharmaceuticals has been granted notice of acceptance for the use of Thymosin Beta 4 (Tß4) by the Australian patent office, which expires in 2023.
Subscribe to our email newsletter
Tß4 is a synthetic version of a naturally occurring peptide present in virtually all human cells. The preclinical studies of this multi-functional molecule has shown to promote endothelial cell differentiation and migration in the heart and central nervous system, promote angiogenesis in dermal and cardiac tissues, increase keratinocyte migration and collagen deposition, and decrease inflammation by down regulating inflammatory cytokines.
RegeneRx claimed that it has identified several molecular variations of Tß4 that may affect the aging of skin, among other properties, and could be important candidates as active ingredients in pharmaceutical and consumer products.
Finkelstein, president and CEO of RegeneRx Biopharmaceuticals, said: “We are pleased to enhance our intellectual property estate for our product candidates and their uses. We currently have more than 60 issued patents and patent applications that expire between 2019 and 2027.”